Therapeutic Solutions International (TSOI) 10-K 22 Apr 16 2013 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2013	Apr. 21, 2016	Jun. 28, 2012
Document and Entity Information:
Entity Registrant Name	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Document Type	10-K
Document Period End Date	Dec. 31, 2013
Trading Symbol	tsoi
Amendment Flag	false
Entity Central Index Key	1,419,051
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		672,951,000
Entity Public Float			$ 2,019,250
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,013
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 12,513	$ 35,011
Inventories	26,798	30,790
Prepaid expenses and other current assets	68,569	14,535
Assets from discontinued operations	21,391	16,358
Total current assets	129,270	96,694
Other non-current assets	12,441	12,410
Property and equipment, net	69,133	92,453
Total assets	210,844	201,557
Current liabilities:
Accounts payable	298,521	230,786
Accrued expenses and other current liabilities	251,354	24,814
Due to related parties	236,324	30,013
Liabilities from discontinued operations	0	48,842
Total current liabilities	786,199	334,454
Long term liabilities:
Due to related parties	0	60,000
Total long term liabilities	0	60,000
Shareholders' Deficit
Preferred stock, $.001 par value; 5,000,000 shares authorized	0	0
Common stock, $.001 par value; 699,999,999 shares authorized, 94,466,400 issued and outstanding at December 31, 2013 and 699,999,999 shares authorized, 305,458,333 issued and outstanding at December 31, 2012	94,466	305,458
Capital in excess of par	1,665,725	1,285,533
Deficit accumulated	(2,335,546)	(1,783,888)
Total shareholders' deficit	(575,355)	(192,897)
Total liabilities and shareholders' deficit	$ 210,844	$ 201,557

Consolidated Balance Sheets Par

Consolidated Balance Sheets Parentheticals - $ / shares	Dec. 31, 2013	Dec. 31, 2012
Parentheticals
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	699,999,999	699,999,999
Common Stock, shares issued	94,466,400	305,458,333
Common Stock, shares outstanding	94,466,400	305,458,333

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenue:
Net international revenues	$ 311,596	$ 354,155
Total revenues	311,596	354,155
Cost of goods sold	11,835	3,543
Gross profit	299,761	350,612
Operating expenses:
Selling	11,515	102,087
General and administrative	68,932	138,490
Salaries, wages, and related costs	520,933	1,188,531
Royalties	0	106,247
Amortization and depreciation	23,320	186,320
Consulting fees	85,515	478,068
Legal and professional fees	149,663	583,023
Total operating expenses	859,879	2,782,766
Net loss from operations	(560,118)	(2,432,154)
Other income (expense):
Expense recapture as result of settlement	0	400,000
Net other income (expense)	22,766	20,268
Interest expense	(10,147)	(36)
Total other income (expense)	12,618	420,232
Net loss from continuing operations	(547,500)	(2,011,922)
Net income (loss) from discontinued operations	(4,158)	1,206,390
Net loss	$ (551,658)	$ (805,532)
Basic and diluted earnings (loss) per common share
Continuing operation	$ (0.01)	$ (0.01)
Discontinued operation.	$ 0	$ 0
Weighted average shares outstanding	86,534,071	305,458,333

Condensed Consolidated Statemen

Condensed Consolidated Statement of Changes in Shareholders' (Deficit) - USD ($)	Common Stock	Common Stock Amount	Additional Paid-in Capital	Earnings (Deficit) Accumulated	Total
Balance at Dec. 31, 2011	305,458,333	305,458	975,281	(978,356)	302,383
Employee stock options vested during the year		$ 0	$ 310,252	$ 0	$ 310,252
Net Loss, December 31, 2012		$ 0	$ 0	$ (805,532)	$ (805,532)
Balance at Dec. 31, 2012	305,458,333	305,458	1,285,533	(1,783,888)	(192,897)
Stock returned & cancelled due to MDRA on January 17, 2013	(223,991,933)	(223,992)	223,992	0	0
Stock issued for service on May 8, 2013	2,000,000	2,000	28,200	0	30,200
Stock options granted June 29, 2013		$ 0	$ 78,000	$ 0	$ 78,000
Stock issued for service on July 10, 2013	2,000,000	2,000	10,000	0	12,000
Stock issued for service on July 15, 2013	4,000,000	4,000	20,000	0	24,000
Stock issued for service on December 2, 2013	5,000,000	5,000	20,000	0	25,000
Net Loss, December 31, 2013		$ 0	$ 0	$ (551,658)	$ (551,658)
Balance at Dec. 31, 2013	94,466,400	94,466	1,665,725	(2,335,546)	(575,355)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities
Net loss	$ (551,658)	$ (805,532)
Non-cash expenses:
Amortization	0	175,000
Depreciation	23,320	11,320
Stock based compensation to consultants	95,200	0
Compensation expense - employee stock option plan	74,000	310,252
Expense recapture as result of settlement	0	(400,000)
Changes in operating assets and liabilities:
(Increase) decrease in inventory	3,992	17,408
(Increase) decrease in accounts receivable	0	4,700
(Increase) decrease in prepaid expenses and other current assets	(54,034)	475,502
(Increase) decrease in other assets	(31)	(60)
Increase (decrease) in accounts payable	116,577	174,010
Increase (decrease) in accrued expenses and other current liabilities	226,540	(14,341)
Increase (decrease) in other related party liabilities	98,083	0
Cash used by operating activities-continuing operations	31,991	(51,741)
Cash used by operating activities-discontinued operations	(53,875)	4,911
Net cash provided by operating activities	(21,884)	(46,830)
Cash flows from investing activities
Acquistion of fixed assets	0	(6,135)
Net cash used by by investing activities	0	(6,135)
Cash flows from financing activities
Borrowing and other advances	36,002	0
Repayments	(36,616)	0
Net cash provided by financing activities	(614)	0
Increase in cash	(22,498)	(52,965)
Cash at beginning of period	35,011	87,976
Cash at end of period	12,513	35,011
Supplemental disclosure of non-cash investing and financing activities:
Increase in fixed assets and due to related parties	0	90,000
Decrease in License agreement and due to related party	0	3,000,000
Supplemental Cash Flow Information:
Cash paid for interest	2,956	36
Cash paid for income taxes	$ 800	$ 800

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2013
Nature of Business:
Nature of Business	Note 1 – Nature of Business Therapeutic Solutions International, Inc. (the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation organized September 21, 2010 (“Splint”). Splint is treated as the “accounting acquirer” in the accompanying financial statements. Until April 28, 2014 the Company sold (directly and through distributors and sublicensees), in non-US countries, plastic intraoral devices known as Anterior Midpoint Stop Appliances (“AMPSA Products”) . On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated. The ostensible reason Mr. Jaczko gave was our failure to make certain unspecified payments due under the license agreement to his clients. We disputed the termination, but believed that the costs involved with litigating the termination of the New License was not in the best interest of the Company and its shareholders. Therefore, the Company moved in a new direction. Currently the Company is involved in the medical sciences market. We are focused on three different areas within the same market. They are outlined as follows: · Dietary Supplements · Immunotherapy, and · Fetal - Maternal Health

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies:
Significant Accounting Policies	Note 2 – Significant Accounting Policies Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2013 and 2012. Other assets include restricted cash of $10,000 that is used to secure a company credit card. Inventory Inventory consists of finished goods, and is stated at the lower of cost or market. The Company records cost of sales using the moving average cost method. There was no excess or obsolete inventory reserve at December 31, 2013 and 2012. Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Intangible Assets Intangible assets consisted primarily of intellectual properties such as regulatory product approvals and patents. The Company does not own any such intangible assets as of December 31, 2013. On August 24, 2012, the Company entered into a New License Agreement, which terminated a prior Exclusive Agreements and continued, for the remainder of 2012, the exclusive worldwide license to make and sell the chairside AMPSA Products, as well as (other than in the United States) dental-laboratory semi-custom AMPSA Products. Beginning on January 1, 2013, the New License Agreement granted the Company a royalty-free nonexclusive worldwide license to make and sell certain products under certain Boyd Parties patent rights and related technology (but excluding the United States market). On April 28, 2014, the Company received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated See Note 5 – License Agreements. Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Going Concern The Company's financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses over the past years which have resulted in stockholders’ accumulated deficits of approximately $2,336 thousand and a working capital deficit of approximately $657 thousand at December 31 2013. These conditions raise uncertainty about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Share Based Expenses ASC 718 "Compensation - Stock Compensation," The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 "Equity-Based Payments to Non-Employees," "Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services". Recently Implemented Standards The Company has implemented all new accounting pronouncements that are in effect that may impact its financial statements and does not believe that there are any new accounting pronouncements that have been issued that might have a material impact on its financial statements.

Restricted Cash

Restricted Cash	12 Months Ended
	Dec. 31, 2013
Restricted Cash:
Restricted Cash	Note 3 – Restricted Cash Other non-current asset is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2016, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2013
Equipment
Equipment	Note 4 – Equipment The cost and accumulated depreciation of fixed assets and equipment at December 31, 2013 and 2012 are summarized below: December 31, 2013 December 31, 2012 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Molding Equipment Interests 90,000 90,000 Total 105,961 105,961 Accumulated Depreciation (36,828) (13,508) Property and Equipment, net $ 69,133 $ 92,453 Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Depreciation expenses for the years ended December 31, 2013 and 2012 were $23,320 and $11,320, respectively.

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2013
License Agreements:
License Agreements	Note 5 – License Agreements The Company had a New License Agreement for the period from August 24, 2012 to December 31, 2012, an exclusive worldwide license with a 30% royalty on net sales (subject to reduction under certain conditions). Also, the New License Agreement granted the Company, for the period from January 1, 2013 forward, a royalty-free nonexclusive worldwide license to make and sell certain products, but excluding the United States market. On April 28, 2014, the Company received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated

Equity Transactions

Equity Transactions	12 Months Ended
	Dec. 31, 2013
Equity Transactions
Equity Transactions	Note 6 – Equity Transactions Preferred Stock The Company is authorized to issue 5,000,000 shares of $.001 par value preferred stock. The Company has not issued any preferred stock. Common Stock The Company is authorized to issue 699,999,999 shares of $.001 par value common stock. All shares have equal voting rights, are non-assessable, and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company. On July 10, 2013, we issued 2,000,000 shares of common stock, valued at $.006 per shares, for legal services. On July 15, 2013, we issued 4,000,000 shares of common stock, valued at $.006 per share, for consulting services. On November 15, 2013, we issued 5,000,000 shares of common stock, valued at $.005 per share, for consulting services. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services. On March 31, 2014, we issued 2,000,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.006 per share, for legal services. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On December 9, 2014, we issued 100,000,000 shares of common stock, valued at $.0035 per share, in regard to a Material Definitive Agreement (Form 8-K filed on December 10, 2014). On April 1, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 11, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On April 11, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On June 1, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On June 1, 2015, we issued 7,000,000 shares of common stock, valued at $.0025 per share, for legal services On June 8, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On August 31, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 9, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 16, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 4,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 31,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On November 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 30, 2015, we issued 5,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On November 30, 2015, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for legal services. On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016). On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On March 21, 2016, we issued 100,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. Warrants On February 20, 2009, the Company granted certain compensatory warrants. The fair value of each compensatory warrant granted is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. Expected volatilities are based on volatilities from the Company's traded common stock since February 20, 2009. As of March 31, 2014 all warrants expired and no warrants were exercised. No warrants were granted by the Company in 2013, 2014 or 2015. The risk-free rate for the periods within the contractual life of the compensatory warrants is based on the U.S. Treasury bond rate in effect at the time of grant for bonds with maturity dates at the estimated term of the warrants. The following values were used to calculate the intrinsic values of the Company’s outstanding compensatory warrants as of their issuance dates: Expected volatility 136.53% - 217.26% Expected dividends 0 Expected term (in years) 2 - 4 Risk-free rate 1.29% - 1.86% A summary of these compensatory warrants outstanding at December 31, 2013 and 2012 and changes during the period is presented below: Warrants Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Exercisable at December 31, 2012 250,000 $1.00 1.25 $ - Granted 0 Exercised 0 Cancelled 0 Exercisable at December 31, 2013 250,000 $1.00 0.25 $ - Stock Based Compensation As of December 31, 2012 the Company had 3,100,000 stock options outstanding. As of December 31, 2013 all options expired or were cancelled by options holders. The Company did not grant any stock options for the years ended December 31, 2014 or December 31, 2015.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions:
Related Party Transactions	Note 7 – Related Party Transactions On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes:
Income Taxes	Note 8 – Income Taxes The Company has net operating losses carried forward of $1,620,213 (2012 – $636,349) available to offset taxable income in future years which expire beginning in fiscal 2031. The Company is subject to United States federal and state income taxes at an approximate rate of 45%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2013 $ December 31, 2012 $ Net loss before income taxes per financial statements (551,658) (805,532) Income tax rate 45% 45% Income tax recovery (248,246) (362,489) Permanent differences 105,885 151,782 Change in valuation allowance 114,243 199,534 Provision for income taxes – – The significant components of deferred income tax assets and liabilities at December 31, 2013 and 2012 are as follows: December 31, 2013 $ December 31, 2012 $ Net operating loss carry-forward 750,592 636,349 Valuation allowance (750,592) (636,349) Net deferred income tax asset – –

Geographic Information

Geographic Information	12 Months Ended
	Dec. 31, 2013
Geographic Information
Geographic Information	Note 9 – Geographic Information The following table provides information related to our 2013 and 2012 revenues: 2013 : Net domestic revenues-discontinued $ -0- Net international revenues 311,596 Total $ 311,596 2012 : Net domestic revenues-discontinued $ 1,837,480 Net international revenues 354,926 Total $ 2,191,635

Discontinued Operation

Discontinued Operation	12 Months Ended
	Dec. 31, 2013
Discontinued Operation:
Discontinued Operation	Note 10 – Discontinued Operation On August 24, 2012 the Company entered into a New License Agreement. The New License Agreement terminated prior Exclusive Agreements. The New License Agreement terminated our rights to sell AMPSA products in the United States market as of December 31, 2012. As of January 1, 2013 the Company under the New License Agreement has the rights to sell AMPSA products under the New License Agreement to non-US markets, royalty-free. The following are the summarized results of discontinued operations for the years ended December 31, 2015 and 2014: December 31, 2013 December 31, 2012 Net domestic revenues $ - $ 1,837,480 Cost of goods sold - 76,586 Selling expenses - 4,440 Royalties (4,158) (550,064) (4,158) 1,206,390 Assets Accounts Receivable, net - 16,358 Total assets of discontinued operations - 16,358 Liabilities Royalties payable, related party - 48,842 Total liabilities of discontinued operations $ - $ 48,842 On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated. The ostensible reason Mr. Jaczko gave was our failure to make certain unspecified payments due under the license agreement to his clients. We disputed the termination, but believed that the costs involved with litigating the termination of the license was not in the best interest of the Company and its shareholders. Therefore, the Company decided to move in new direction.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events:
Subsequent Events	Note 11 – Subsequent Events On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services. On March 31, 2014, we issued 2,000,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.006 per share, for legal services. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On December 9, 2014, we issued 100,000,000 shares of common stock, valued at $.0035 per share, in regard to a Material Definitive Agreement (Form 8-K filed on December 10, 2014). On April 1, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 11, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On April 11, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On June 1, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On June 1, 2015, we issued 7,000,000 shares of common stock, valued at $.0025 per share, for legal services On June 8, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On August 31, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 9, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 16, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 4,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 31,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On November 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 30, 2015, we issued 5,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On November 30, 2015, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for legal services. On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016). On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On March 21, 2016, we issued 100,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. The Company previously reported, on April 29, 2013 a former employee of the Company, Reid Jilek, sued the Company, its two directors and its three officers in San Diego County (California) Superior Court for breach of contract, retaliation, constructive discharge, failure to pay wages, failure to reimburse, conversion and fraudulent inducement. The complaint related to his employment agreement with the Company and his resignation which was effective in January 2013. The trial was held in September 2014. On September 26, 2014 the Court ruled in favor of the Company and against all of Jilek's claims, and ruled that the Company was the prevailing party, and therefore was entitled to recover its attorney’s fees and costs from Jilek. The Company did not prevail in its cross-claims against Jilek. Jilek's claims against the Company’s directors and officers had previously been dismissed. On December 9, 2014 the Company completed sales of its unregistered restricted common shares to Innovative Supplements, Inc., and Robert F. Graham. The Company sold a total of one hundred million (100,000,000) shares of unregistered restricted common stock at par value ($0.001) per share in exchange for (i) an assignment of Seller and Shareholder’s contractual right, title and interest in and to proprietary formulations for two nutritional supplement products known under the trade names: (a) “T-Rx”; and, (b) “Vital Female; and, (ii) the purchase of all legal right, title and interest, in and to intellectual property including, but not limited to, Innovative’s nutritional supplement product known under the trade name: “Projuvenol.” On July 8, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/190170 titled “Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions”. On July 21, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/194990 titled “Prevention of Pregnancy Complications by Probiotic Administration”. On September 02, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/213260 titled “Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications”. On September 15, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/219020 titled “Diagnostic Methods For The Assessment Of Pregnancy Complications”. On September 25, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/232722 titled “A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth”. On October 20, 2015, OmniBiome, Inc, a wholly owned subsidiary of the Company, was incorporated in the State of Delaware. On October 28, 2015, MolecuVax, Inc, a wholly owned subsidiary of the Company, was incorporated in the State of Delaware. On November 18, 2015, Therapeutic Solutions International, Inc. licensed certain intellectual property to OmniBiome, Inc., a wholly owned subsidiary of Therapeutic Solutions International, Inc., as follows: (1) Application No. 62/213260 titled “Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications” covers utility of vaccines and various agents to alter pathological conditions in which the maternal immune system induces a process of inflammation that culminates in placental alterations leading to either fetal loss or preterm labor; (2) Application No. 62/219020 “Diagnostic Methods For The Assessment Of Pregnancy Complications” a cytokine-based diagnostic kit aimed at stratifying risk of preterm labor and other pregnancy associated complications; and (3) Application No. 62/232722 “A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth” covering various medical devices aimed at immune modulating the cervical microenvironment in order to prevent preterm labor. On November 20, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/258007 titled “Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer”. On December 04, 2015, Therapeutic Solutions International, Inc. licensed certain intellectual property to OmniBiome, Inc., a wholly owned subsidiary of Therapeutic Solutions International, Inc., Application No. 62/194990 titled “Prevention of Pregnancy Complications by Probiotic Administration.” On January 21, 2016, our Board of Directors elected Thomas E. Ichim, Ph.D, to fill a vacant seat on our Board of Directors. On February 05, 2016, Therapeutic Solutions International, Inc. licensed certain intellectual property to MolecuVax, Inc., a wholly owned subsidiary of Therapeutic Solutions International, Inc., Application No. 62/258,007 titled “Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer.”

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies:
Estimates	Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash, Policy	Cash For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2013 and 2012. Other assets include restricted cash of $10,000 that is used to secure a company credit card.
Inventory	Inventory Inventory consists of finished goods, and is stated at the lower of cost or market. The Company records cost of sales using the moving average cost method. There was no excess or obsolete inventory reserve at December 31, 2013 and 2012.
Depreciation and Amortization, Policy	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement.
Intangible Assets, Policy	Intangible Assets Intangible assets consisted primarily of intellectual properties such as regulatory product approvals and patents. The Company does not own any such intangible assets as of December 31, 2013. On August 24, 2012, the Company entered into a New License Agreement, which terminated a prior Exclusive Agreements and continued, for the remainder of 2012, the exclusive worldwide license to make and sell the chairside AMPSA Products, as well as (other than in the United States) dental-laboratory semi-custom AMPSA Products. Beginning on January 1, 2013, the New License Agreement granted the Company a royalty-free nonexclusive worldwide license to make and sell certain products under certain Boyd Parties patent rights and related technology (but excluding the United States market). On April 28, 2014, the Company received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated See Note 5 – License Agreements.
Income Taxes, Policy	Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”
Going Concern	Going Concern The Company's financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses over the past years which have resulted in stockholders’ accumulated deficits of approximately $2,336 thousand and a working capital deficit of approximately $657 thousand at December 31 2013. These conditions raise uncertainty about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Share Based Expenses	Share Based Expenses ASC 718 "Compensation - Stock Compensation," The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 "Equity-Based Payments to Non-Employees," "Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services".
Recently Implemented Standards	Recently Implemented Standards The Company has implemented all new accounting pronouncements that are in effect that may impact its financial statements and does not believe that there are any new accounting pronouncements that have been issued that might have a material impact on its financial statements.

Schedule of Cost and accumulate

Schedule of Cost and accumulated depreciation of fixed assets and equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Cost and accumulated depreciation of fixed assets and equipment:
Schedule of Cost and accumulated depreciation of fixed assets and equipment	The cost and accumulated depreciation of fixed assets and equipment at December 31, 2013 and 2012 are summarized below: December 31, 2013 December 31, 2012 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Molding Equipment Interests 90,000 90,000 Total 105,961 105,961 Accumulated Depreciation (36,828) (13,508) Property and Equipment, net $ 69,133 $ 92,453

Schedule of Equity Transactions

Schedule of Equity Transactions (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Equity Transactions (Tables)
Schedule of Values used to calculate intrinsic values of the Company's outstanding compensatory warrants	The following values were used to calculate the intrinsic values of the Company’s outstanding compensatory warrants as of their issuance dates: Expected volatility 136.53% - 217.26% Expected dividends 0 Expected term (in years) 2 - 4 Risk-free rate 1.29% - 1.86%
Schedule of Summary of compensatory warrants outstanding	A summary of these compensatory warrants outstanding at December 31, 2013 and 2012 and changes during the period is presented below: Warrants Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Exercisable at December 31, 2012 250,000 $1.00 1.25 $ - Granted 0 Exercised 0 Cancelled 0 Exercisable at December 31, 2013 250,000 $1.00 0.25 $ -

Schedule of Income Expense Bene

Schedule of Income Expense Benefit (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Income Expense Benefit (Tables):
Schedule of Effective Income Tax Rate Reconciliation	The Company is subject to United States federal and state income taxes at an approximate rate of 45%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2013 $ December 31, 2012 $ Net loss before income taxes per financial statements (551,658) (805,532) Income tax rate 45% 45% Income tax recovery (248,246) (362,489) Permanent differences 105,885 151,782 Change in valuation allowance 114,243 199,534 Provision for income taxes – –
Schedule of Deferred Tax Assets and Liabilities	The significant components of deferred income tax assets and liabilities at December 31, 2013 and 2012 are as follows: December 31, 2013 $ December 31, 2012 $ Net operating loss carry-forward 750,592 636,349 Valuation allowance (750,592) (636,349) Net deferred income tax asset – –

Schedule of Geographic Informat

Schedule of Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Geographic Information:
Schedule of Information related to 2012 and 2013 revenues	The following table provides information related to our 2013 and 2012 revenues: 2013 : Net domestic revenues-discontinued $ -0- Net international revenues 311,596 Total $ 311,596 2012 : Net domestic revenues-discontinued $ 1,837,480 Net international revenues 354,926 Total $ 2,191,635

Schedule of Discontinued Operat

Schedule of Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Discontinued Operations:
Schedule of Summary of results of discontinued operations	The following are the summarized results of discontinued operations for the years ended December 31, 2015 and 2014: December 31, 2013 December 31, 2012 Net domestic revenues $ - $ 1,837,480 Cost of goods sold - 76,586 Selling expenses - 4,440 Royalties (4,158) (550,064) (4,158) 1,206,390 Assets Accounts Receivable, net - 16,358 Total assets of discontinued operations - 16,358 Liabilities Royalties payable, related party - 48,842 Total liabilities of discontinued operations $ - $ 48,842

Organization and Presentation (

Organization and Presentation (Details) - USD ($)	Jan. 18, 2013	Aug. 24, 2012	Dec. 31, 2011	Sep. 21, 2010
Organization and Presentation:
Issued common shares to the shareholders of Splint				250,523,333
Deferred license inception fee			$ 3,000,000
Agreed to surrender shares of common stock		223,991,933
Reduced number of total outstanding common shares to	81,466,400

Cash (Details)

Cash (Details)	Dec. 31, 2013USD ($)
Cash Details
Other assets include restricted cash	$ 10,000

Going Concern (Details)

Going Concern (Details)	Dec. 31, 2013USD ($)
Going Concern Details
Accumulated deficit (approx)	$ 2,335,000
Working capital deficit (approx)	$ 657,000

Restricted Cash Consists Of (De

Restricted Cash Consists Of (Details)	Dec. 31, 2013USD ($)
Restricted Cash Details
Other non-current asset certificate of deposit	$ 10,000
Annual interest rate	0.60%

Equipment (Details)

Equipment (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Equipment Consists Of the Following:
Computer Hardware	$ 10,747	$ 10,747
Office Furniture and Equipment	3,639	3,639
Shipping and Other Equipment	1,575	1,575
Molding Equipment Interests	90,000	90,000
Total Equipment	105,961	105,961
Accumulated Depreciation	(36,828)	(13,508)
Property and equipment, net	$ 69,133	$ 92,453

License (Details)

License (Details)	Dec. 31, 2012
License Agreements Consists Of the Following:
New License Agreement for an exclusive worldwide license with a royalty on net sales percent	30.00%

Capital Stock Transactions (Det

Capital Stock Transactions (Details) - $ / shares	Dec. 31, 2013	Dec. 31, 2012
PREFERRED STOCK:
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, par value	$ 0.001	$ 0.001
COMMON STOCK:
Common Stock, shares authorized	699,999,999	699,999,999
Common Stock, par value	$ 0.001	$ 0.001
Voting rights	50.00%
Stock based compensation stock options outstanding shares	3,100,000	3,100,000

Capital Stock Transactions Duri

Capital Stock Transactions During 2013 (Details) - $ / shares	Nov. 15, 2013	Jul. 15, 2013	Jul. 10, 2013
Capital Stock Transactions During 2013
Issued shares of common stock for legal services			2,000,000
Issued shares of common stock for legal services per share			$ 0.006
Issued shares of common stock for consulting services	5,000,000	4,000,000
Issued shares of common stockfor consulting services per share	$ 0.005	$ 0.006

Capital Stock Transactions Du32

Capital Stock Transactions During 2014 (Details) - $ / shares	Dec. 09, 2014	Sep. 30, 2014	Jun. 19, 2014	Mar. 31, 2014
Capital Stock Transactions During 2014 (Details)
Issued shares of common stock for consulting services				2,500,000
Issued shares of common stockfor consulting services per share				$ 0.0035
Issued shares of common stock for consulting services				2,500,000
Issued shares of common stockfor consulting services per share				$ 0.004
Issued shares of common stock for consulting services				2,000,000
Issued shares of common stockfor consulting services per share				$ 0.0035
Issued shares of common stock for legal services				2,500,000
Issued shares of common stock for legal services per share				$ 0.006
Issued shares of common stock for a conversion of notes payable for accrued wages		26,562,500	45,000,000
Issued shares of common stock for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,476,435	45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		26,562,500
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,250,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		7,682,165
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stockin regard to a Material Definitive Agreement	100,000,000
Issued shares of common stockin regard to a Material Definitive Agreement per share	$ 0.004

Capital Stock Transactions Du33

Capital Stock Transactions During 2015 (Details) - $ / shares	Nov. 30, 2015	Nov. 17, 2015	Nov. 16, 2015	Nov. 09, 2015	Aug. 31, 2015	Jun. 08, 2015	Jun. 01, 2015	Apr. 17, 2015	Apr. 11, 2015	Apr. 01, 2015
Capital Stock Transactions During 2015
Shares of common stock for consulting services	5,000,000	31,500,000					3,000,000		20,000,000	10,000,000
Shares of common stock for consulting services per share	$ 0.0025	$ 0.0025					$ 0.0025		$ 0.0025	$ 0.0025
Shares of common stock for Private Placement		4,000,000	20,000,000	3,000,000	10,000,000	1,000,000		20,000,000	20,000,000
Shares of common stock for Private Placement per share		$ 0.0025	$ 0.0025	$ 0.0025	$ 0.0025	$ 0.0025		$ 0.0025	$ 0.0025
Shares of common stock for legal services	2,500,000						7,000,000
Shares of common stock for legal services per share	$ 0.0025						$ 0.0025
Shares of common stock issued		20,000,000
Shares of common stock, valued at per share		$ 0.0025

Capital Stock Transactions Du34

Capital Stock Transactions During 2016 (Details) - $ / shares	Mar. 21, 2016	Mar. 07, 2016	Feb. 26, 2016	Feb. 22, 2016	Feb. 05, 2016	Feb. 01, 2016	Jan. 22, 2016	Jan. 04, 2016
Capital Stock Transactions During 2016
Issued shares of common stock for consulting services	100,000,000	10,000,000				2,500,000	2,500,000	2,500,000
Issued shares of common stockfor consulting services per share	$ 0.0025	$ 0.0025				$ 0.0025	$ 0.0025	$ 0.0025
Issued shares of common stock for for an investment in Private Placement			1,000,000		8,000,000
Issued shares of common stock for an investment in Private Placement per share			$ 0.0025		$ 0.0025
Issued shares of common stock in regard to a License Agreement				5,451,000
Issued shares of common stock in regard to a License Agreement per share				$ 0.0030

Outstanding Compensatory Warran

Outstanding Compensatory Warrants (Details)	Dec. 31, 2013
Outstanding Compensatory Warrants:
Expected volatility minimum	136.53%
Expected volatility maximum	217.26%
Expected dividends	0.00%
Expected term (in years) minimum	2
Expected term (in years) maximum	4
Risk-free rate minimum	1.29%
Risk-free rate maximum	1.86%

Compensatory Warrants Outstandi

Compensatory Warrants Outstanding and changes during the period (Details)	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2012USD ($)$ / sharesshares
Compensatory Warrants Outstanding and changes during the period
Exercisable	250,000	250,000
Granted	0	0
Exercised	0	0
Cancelled	0	0
Weighted-Average Exercise Price
Weighted-Average Exercise Price Exercisable | $ / shares	$ 1	$ 1
Weighted-Average Remaining Contractual Term Exercisable	1.25	0.25
Aggregate Intrinsic Value Exercisable | $	$ 0	$ 0

Related Party Transactions Agre

Related Party Transactions Agreement (Details) - $ / shares	Sep. 30, 2014	Jun. 19, 2014
Related Party Transactions Agreement:
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages	26,562,500	45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share	$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages	21,476,435	45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share	$ 0.002	$ 0.003
Shares of common stock to an officer for a conversion of notes payable for accrued wages	26,562,500
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share	$ 0.002
Shares of common stock to an officer for a conversion of notes payable for accrued wages	21,250,000
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share	$ 0.002
Shares of common stock to an officer for a conversion of notes payable for accrued wages	7,682,165
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share	$ 0.002

Income taxes (Narrative) (Detai

Income taxes (Narrative) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Income Taxes Narrative Details
Net operating losses carried forward	$ 1,620,213	$ 636,349

Income Taxes Reconciliation (De

Income Taxes Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes Reconciliation Details
Net loss before income taxes per financial statements	$ (551,658)	$ (805,532)
Income tax rate	45.00%	45.00%
Income tax recovery	$ (248,246)	$ (362,489)
Permanent differences	105,885	151,782
Change in valuation allowance	114,243	199,534
Provision for income taxes	$ 0	$ 0

Significant components of defer

Significant components of deferred income tax assets and liabilities (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Significant components of deferred income tax assets and liabilities Details
Net operating loss carry-forward	$ 750,592	$ 636,349
Valuation allowance	(750,592)	(636,349)
Net deferred income tax asset	$ 0	$ 0

Geographic Information During T

Geographic Information During The Period (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Geographic Information During The Period:
Net domestic revenues-discontinued	$ 0	$ 1,837,480
Net international revenues	311,596	354,926
Total Revenues	$ 311,596	$ 2,191,635

Results of discontinued operati

Results of discontinued operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Results of discontinued operations details
Net domestic revenues	$ 0	$ 1,837,480
Cost of goods sold	0	76,586
Selling expenses	0	4,440
Royalties	0	(550,064)
Net income (loss) from discontinued operations	(4,158)	1,206,390
Assets discontinued operations
Accounts Receivable, net	0	16,358
Total assets of discontinued operations	0	16,358
Liabilities discontinued operations
Royalties payable, related party	0	48,842
Liabilities from discontinued operations	$ 0	$ 48,842

Subsequent Events During 2014 (

Subsequent Events During 2014 (Details) - $ / shares	Dec. 09, 2014	Sep. 30, 2014	Jun. 19, 2014	Mar. 31, 2014
Subsequent Events During 2014 Details
Issued shares of common stock for consulting services				2,500,000
Issued shares of common stockfor consulting services per share				$ 0.0035
Issued shares of common stock for consulting services				2,500,000
Issued shares of common stockfor consulting services per share				$ 0.004
Issued shares of common stock for consulting services				2,000,000
Issued shares of common stockfor consulting services per share				$ 0.0035
Issued shares of common stock for legal services				2,500,000
Issued shares of common stock for legal services per share				$ 0.006
Issued shares of common stock for a conversion of notes payable for accrued wages		26,562,500	45,000,000
Issued shares of common stock for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,476,435	45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		26,562,500
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,250,000	45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		7,682,165
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stockin regard to a Material Definitive Agreement	100,000,000
Issued shares of common stockin regard to a Material Definitive Agreement per share	$ 0.0035
Sold shares of unregistered restricted common stock to Innovative Supplements, Inc., and Robert F. Graham	100,000,000
Sold shares of unregistered restricted common stock, par value	$ 0.001

Subsequent Events During 2015 (

Subsequent Events During 2015 (Details) - $ / shares	Nov. 30, 2015	Nov. 17, 2015	Nov. 16, 2015	Nov. 09, 2015	Aug. 31, 2015	Jun. 08, 2015	Jun. 01, 2015	Apr. 17, 2015	Apr. 11, 2015	Apr. 01, 2015
Subsequent Events During 2015 Details
Shares of common stock for consulting services	5,000,000	31,500,000					3,000,000		20,000,000	10,000,000
Shares of common stock for consulting services per share	$ 0.0025	$ 0.0025					$ 0.0025		$ 0.0025	$ 0.0025
Shares of common stock for Private Placement		4,000,000	20,000,000	3,000,000	10,000,000	1,000,000		20,000,000	20,000,000
Shares of common stock for Private Placement per share		$ 0.0025	$ 0.0025	$ 0.0025	$ 0.0025	$ 0.0025		$ 0.0025	$ 0.0025
Shares of common stock for legal services	2,500,000						7,000,000
Shares of common stock for legal services per share	$ 0.0025						$ 0.0025
Shares of common stock for Private Placement		20,000,000
Shares of common stock for Private Placement per share		$ 0.0025

Subsequent Events During 2016 (

Subsequent Events During 2016 (Details) - $ / shares	Mar. 21, 2016	Mar. 07, 2016	Feb. 26, 2016	Feb. 22, 2016	Feb. 05, 2016	Feb. 01, 2016	Jan. 22, 2016	Jan. 04, 2016
Subsequent Events During 2016
Issued shares of common stock for consulting services	100,000,000	10,000,000				2,500,000	2,500,000	2,500,000
Issued shares of common stockfor consulting services per share	$ 0.0025	$ 0.0025				$ 0.0025	$ 0.0025	$ 0.0025
Issued shares of common stock for for an investment in Private Placement			1,000,000		8,000,000
Issued shares of common stock for an investment in Private Placement per share			$ 0.0025		$ 0.0025
Issued shares of common stock in regard to a License Agreement				5,451,000
Issued shares of common stock in regard to a License Agreement per share				$ 0.0030